

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
26 June 2008 (26.06.2008)

PCT

(10) International Publication Number  
**WO 2008/074978 A1**

(51) International Patent Classification:  
*A61Q 11/00* (2006.01) *A61K 8/97* (2006.01)

BUCKLEY, Catherine [GB/GB]; Mars UK Limited, Waltham Centre for Pet Nutrition, Freeby Lane, Waltham-on-the-Wolds, Leicestershire LE14 4RT (GB).

(21) International Application Number:  
PCT/GB2007/004522

(74) Agents: CARE, Alison et al.; Kilburn & Strode, 20 Red Lion Street, London WC1R 4PJ (GB).

(22) International Filing Date:  
27 November 2007 (27.11.2007)

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0625429.6 20 December 2006 (20.12.2006) GB

(71) Applicant (*for all designated States except US*): MARS UK LIMITED [GB/GB]; 3D Dundee Road, Slough SL1 4RT (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): MARSHALL-JONES, Zoe [GB/GB]; Mars UK Limited, Waltham Centre for Pet Nutrition, Freeby Lane, Waltham-on-the-Wolds, Leicestershire LE14 4RT (GB). BAILLON, Marie, Louise [GB/GB]; Mars UK Limited, Waltham Centre for Pet Nutrition, Freeby Lane, Waltham-on-the-Wolds, Leicestershire LE14 4RT (GB).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:  
— with international search report

(54) Title: ORAL HEALTH COMPOSITION COMPRISING ALCHEMILLA VULGARIS

(57) Abstract: The present invention relates to *Alchemilla vulgaris* for use in oral health applications, an oral composition comprising *Alchemilla vulgaris*, and the use of *Alchemilla vulgaris* or the composition, in the improvement or maintenance of oral health in an animal, preferably through the reduction or control of dental plaque and/or alteration of the bacterial content of dental plaque, in the oral cavity of the animal. The invention also includes *Alchemilla vulgaris* for use in the prevention or treatment of gingivitis in an animal. The invention also provides a method for improving or maintaining oral health in an animal.

WO 2008/074978 A1

## 1

ORAL HEALTH COMPOSITION COMPRISING *ALCHEMILLA VULGARIS*

The present invention relates to *Alchemilla vulgaris* for use in oral health applications, an oral composition comprising *Alchemilla vulgaris* , and the use of *Alchemilla vulgaris* or the composition, in the improvement or maintenance of oral health in an animal, preferably through the reduction or control of dental plaque and/or alteration of the bacterial content of dental plaque, in the oral cavity of the animal. The invention also includes *Alchemilla vulgaris* for use in the prevention or treatment of gingivitis in an animal. The invention also provides a method for improving or maintaining oral health in an animal.

The need to maintain or improve oral health in an animal is of great importance. Poor oral health can lead to gum disease (gingivitis) and ultimately tooth loss, which can have severe effects on the wellbeing of the animal.

Poor oral health can be caused by a number of diseases and conditions. One of the most prevalent amongst cats and dogs is periodontal disease. Periodontal disease affects all cats and dogs at some stage during their lives. The aetiological agent in all cases of periodontal disease is plaque.

Current dietary methods for reducing or controlling plaque formation (and therefore associated conditions, such as gingivitis), in companion animals are usually mechanical means, such as hard chews or treats which act to scrape the plaque from the teeth, when chewed or consumed by the animal. The mechanical means rely on texture for their efficacy and a chewy rather than brittle texture is preferable to resist breakage of the means and therefore to also increase tooth cleaning time during chewing. Cats are less keen than dogs to chew for prolonged periods. Therefore products for various animals differ in texture to allow for these different preferences.

Textured toys may also be employed, to remove plaque mechanically from the surface of the teeth, without the animal ingesting any of the product that provides the textured surface.

However, the removal of plaque by mechanical means such as textured foodstuffs or toys relies upon the animal spending sufficient time chewing the mechanical means to scrape the plaque from the surface of the teeth. The amount of time required is  
5 difficult to assess and to monitor. In addition, plaque control on all tooth surfaces in the oral cavity is difficult to achieve via mechanical abrasion alone and certain teeth receive more efficient cleaning than others.

Plaque may also be removed or reduced by cleaning the teeth by brushing. However,  
10 owner compliance with toothbrushing is poor, with the result that very few dogs and cats receive a daily oral care regime of toothbrushing.

As an alternative to mechanical means for the removal of plaque, certain synthetic compounds such as chlorhexidine and triclosan can be used as antibacterial agents to  
15 reduce plaque. However, these compounds are broad spectrum antibacterial agents and, as such, may cause an imbalance in healthy gut microflora populations when ingested regularly. In addition, certain plaque bacteria have been associated with periodontal health and treatment with broad spectrum antibacterials would potentially kill these populations and would actually result in a less healthy oral microflora,  
20 leading to a reduction in oral health.

Accumulation of bacterial biofilms on the surface of a tooth can lead to gingivitis if not sufficiently addressed. Gingivitis is an inflammation of the gums caused by bacterial plaque that accumulates on the gum line. It can cause soreness, redness and  
25 bleeding of the gums.

An additional contributory factor to poor oral health is calculus. Since calculus cannot be removed by toothbrushing in normal cases, it accumulates on the tooth surface and irritates the gum tissue, giving rise to gingivitis. This is a further  
30 indication of poor or deteriorating oral health.

## 3

The addition of calculus formation inhibitors such as sodium tripolyphosphate to pet foodstuffs and to human oral care products helps to prevent calculus accumulation. However, this does not address the bacterial community composition within the dental plaque that is contributing to the detrimental effects of periodontal disease on the oral health of the animal.

Therefore, there is a need for reducing the effects of dental plaque in an animal, in particular by natural methods, without relying solely on mechanical means or synthetic chemicals or compounds and without stressing the animal. Furthermore, there remains a need for the prevention and treatment of gingivitis in an animal.

Accordingly, the present invention provides *Alchemilla vulgaris* for use in improving or maintaining oral health in an animal.

*Alchemilla vulgaris* (*Myrtus communis*) is a flowering plant in the family Myrtaceae, native to southern Europe and north Africa.

The inventors have unexpectedly found that *Alchemilla vulgaris* is able to improve and/or maintain oral health in an animal.

Preferably, the *Alchemilla vulgaris* improves or maintains the oral health of the animal by controlling or reducing dental plaque in the animal, by which it is meant that disease causing factors produced by the plaque and/or dental plaque is reduced in the oral cavity of the animal.

Dental plaque is a mixed microbial community consisting of aerobic and anaerobic bacteria. Although plaque may vary between individuals the formation process can be broken down into three key events of (i) primary colonisation (adhesion); (ii) secondary colonisation (coaggregation); and (iii) maturation (virulence).

Plaque development begins with a tooth surface covered with a film of proteins and glycoproteins called the tooth salivary pellicle. Pioneer bacterial species adhere to

molecules within the salivary pellicle, first forming a monolayer and subsequently pallsades of bacteria perpendicular to the tooth surface.

5 The microbe is held for a brief period by a weakly attractive force, during which time a number of specific adhesion mechanisms hold the cell close to the surface for a significant time period. These specific interactions may be a combination of lectin-like, electrostatic and hydrophobic interactions that in some instances could involve delicate structures called fibrils or fimbriae that project from the cell surface. Following this, initial attachment is rendered effectively irreversible by the production  
10 of extra-cellular polymers.

In humans streptococci are the most common primary colonisers making up between 47-52% of all bacteria adhering to the salivary pellicle.

15 During and after this initial phase, secondary colonisation by a variety of bacteria occurs leading to a large increase in bacterial diversity. Foremost among the events of secondary colonisation is the process of coaggregation whereby the primary colonisers now act as the substrate for colonisation.

20 Coaggregation has been described as 'the recognition between surface molecules on two different bacterial cell types so that a mixed cell aggregate is formed'. It has also be described as 'the adherence among partner cells in a suspension'.

25 Coaggregation is a highly specific process that takes place between specific bacterial 'partners'. Each strain has its own set of partners and mechanisms of cell-cell recognition. Groups of strains also exist which are able to coaggregate with several other strains. Based on human studies, one such organism that dominates these later colonisers is *Fusobacterium nucleatum*, which is a dominant organism in mature dental plaque.

30

Coaggregation is known to play an important role in human plaque formation. Coaggregation between different strains of canine oral bacteria has been determined

## 5

*in vitro* suggesting a similar role for this behaviour in dental plaque formation and development in other animals.

5 At some point during the development of the plaque biofilm, the rate of change in the overall composition slows. The point at which this happens is currently unknown, although it is thought to take several days for the biofilm to reach this state.

10 In human plaque, a succession of bacterial species occurs as Gram-positive cocci and rods are progressively replaced by Gram-negative filamentous and flagellated organisms. The maturing biofilm also tends to become increasingly anaerobic as it increases in depth.

15 It is at this point that the biofilm can be said to have reached a climax community, where a number of the bacteria are reliant on others within the biofilm for their survival. It is during this phase that many organisms associated with periodontal disease are present. These bacteria produce a number of compounds that are the causative factor of periodontal disease, such as proteases and haemolysins. Proteases, in particular trypsin, are reported to have a host of abilities, including the ability to degrade immunoglobulins, inactivate cytokines and their receptors, degrade host  
20 tissues and promote bleeding in the oral cavity. The bacteria of the plaque is known as the plaque biomass.

25 Pathogenic bacteria, such as *Peptostreptococcus* are often present in dental plaque, as well as black pigmenting anaerobes, such as *Porphyromonas*, *Bacteroides* and *Prevotella*, all of which are thought to contribute to disease states.

30 The *Alchemilla vulgaris* of the invention is useful for inhibiting the formation of such biofilms and/or inhibiting the detrimental activities of the biofilm and therefore improving or maintaining oral health by controlling or reducing dental plaque in an animal. The *Alchemilla vulgaris* of the invention is also provided for the prevention or treatment of gingivitis in an animal.

## 6

By reducing the level of pathogenic bacteria in the biofilm, the health of the dental plaque is improved. Thus, the *Alchemilla vulgaris* of the invention is useful in altering the bacterial content of the plaque, preferably by reducing the pathogenic bacterial content of the plaque in the oral cavity of an animal. The *Alchemilla vulgaris* may also promote the healthy bacteria of the plaque. The *Alchemilla vulgaris* of the invention is useful in improving the health of the dental plaque present in the oral cavity of an animal.

The *Alchemilla vulgaris* of the invention preferably reduces the level of inflammatory proteases and/or black pigmenting anaerobes in dental plaque in an animal. These are key disease causing agents that are found in dental plaque.

Most preferably, *Alchemilla vulgaris* inhibits or reduces pathogenic bacteria in dental plaque, which may include *Peptostreptococcus sp.*

The *Alchemilla vulgaris* of the invention is suitable for any animal including a human. However, in a preferred embodiment the animal is a companion animal or a human. By companion animal it is meant any animal that is kept as a pet, which includes a cat, a dog, a horse, a rabbit, or a guinea pig. Preferably, the composition is for a cat or a dog or a human.

The skilled person understands that other names are used to refer to *Alchemilla vulgaris*.

The *Alchemilla vulgaris* of the invention can be the whole plant or a part thereof. It may be the root, bark, stem, leaf or any combination thereof. The *Alchemilla vulgaris* may be dried, crushed, ground or shredded. Preferably, the *Alchemilla vulgaris* is *Alchemilla vulgaris* bark.

Additionally or alternatively an extract of *Alchemilla vulgaris* may be used. Suitable extracts include a methanol extract, ethanol extract, a chloroform extract or a water extract.

A second aspect of the invention provides an oral composition comprising *Alchemilla vulgaris*.

5     The *Alchemilla vulgaris* may comprise between 0.1%-20% by weight of the composition, more preferably 1-15% by weight, more preferably 3-10% by weight, or 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10% by weight. Most preferably, the *Alchemilla vulgaris* comprises about 3% by weight of the composition.

10    The composition may comprise *Alchemilla vulgaris* as the only active ingredient with respect to the improvement or maintenance of oral health. Alternatively, the composition may comprise *Alchemilla vulgaris* as part of a cocktail including one or more further oral health improving or maintaining, or plaque reducing or controlling components.

15    Hereinafter in this text, the term "oral composition" covers all compositions that come into contact with the oral cavity, preferably the surface of a tooth of an animal, including a foodstuff, diet and supplement. Any of these forms may be solid, semi-solid or liquid. The composition may be a paste or a gel.

20    The composition may be in the form of a supplement to be added to any foodstuff that does not contain sufficient levels of *Alchemilla vulgaris* to improve or maintain oral health including prevention or treatment of gingivitis, or to control or reduce dental plaque in an animal, by way of reduction or inhibition of disease causing factors  
25    and/or biomass in the plaque.

The concentration of *Alchemilla vulgaris* in the supplement may be used in addition to the animal's main diet or foodstuff. This can be done by including a quantity of the supplement with the animal's diet or by additionally feeding the animal a quantity of  
30    the supplement. The supplement can be formed as a foodstuff with extremely high levels of the *Alchemilla vulgaris* composition of the invention, which requires dilution before feeding to the animal. The supplement may be in any form, including



solid (e.g. a powder), semi-solid (e.g. a food-like consistency/gel), a liquid, a paste or alternatively, it may be in the form of a tablet or capsule. The liquid can conveniently be mixed in with the food or fed directly to the animal, for example via a spoon or via a pipette-like device. The supplement may be high in one or more components of the invention or may be in the form of a combined pack of at least two parts, each part containing the required level of one or more component.

Preferably the *Alchemilla vulgaris* or a composition comprising *Alchemilla vulgaris* is incorporated into a commercial petfood product composition or a commercial dietary supplement composition. The petfood product may be a dry, semi-dry, a moist or a liquid (drink) product. Moist products include food which is sold in tins or foil containers and has a moisture content of 70 to 90%. Dry products include food which have a similar composition, but with 5 to 15% moisture and presented as biscuit-like kibbles. When the composition comprises a diet, foodstuff or supplement, it is preferably packaged. In this way the consumer is able to identify, from the packaging, the ingredients in the food and identify that it is suitable for the animal in question. The packaging may be metal (usually in the form of a tin or flexifoil), plastic, paper or card. The amount of moisture in any product may influence the type of packaging which can be used or is required.

20

The composition according to the present invention encompasses any product which an animal may consume in its diet. Thus, the invention covers standard food products for humans or other animals, as well as pet food snacks (for example snack bars, biscuits and sweet products). The composition may be a cooked product. It may incorporate meat or animal derived material (such as beef, chicken, turkey, lamb, blood plasma, marrowbone etc, or two or more thereof). The composition alternatively may be meat free (preferably including a meat substitute such as soya, maize gluten or a soya product) in order to provide a protein source. The composition may contain additional protein sources such as soya protein concentrate, milk proteins, gluten etc. The composition may also contain a starch source such as one or more grains (e.g. wheat, corn, rice, oats, barely etc) or may be starch free. A typical dry commercial dog and cat food contains about 30% crude protein, about 10-20% fat

30

and the remainder being carbohydrate, including dietary fibre and ash. A typical wet, or moist product contains (on a dry matter basis) about 40% fat, 50% protein and the remainder being fibre and ash. The composition of the present invention is particularly relevant for a foodstuff as herein described which is sold as a diet,  
5 foodstuff or supplement for a cat, a dog or any other companion animal or a human.

In the present text the terms “domestic” dog and “domestic” cat mean dogs and cats, in particular *Felis domesticus* and *Canis domesticus*.

10 The composition may be applied to or incorporated within a chew or treat which the animal may consume in addition to a main meal foodstuff. The composition may be provided as a coating on or incorporated within a main meal foodstuff.

Alternatively, the composition may be a liquid, gel, paste or the like which may be  
15 applied as a coating to a non-consumable product, such as a toy for an animal. The composition may be incorporated within the product. When the animal chews the toy, the composition comes into contact with some or all of the oral cavity of the animal and improves or maintains the oral health of the animal.

20 When the composition is incorporated within or coated onto a chewy or hard product, the additional benefit of improving or maintaining the oral health of the animal by removing plaque through the mechanical action of the product against the teeth of the animal is achieved, as well as by the action of the *Alchemilla vulgaris* in the composition.

25 The inhibition of certain plaque biofilm forming bacteria by *Alchemilla vulgaris* results in the control or reduction of dental plaque in an animal by the reduction of the bacterial content of the dental plaque.

30 The composition may be used for an animal with any level of oral health in order to improve or maintain oral health in the animal.

## 10

The composition may be used for an animal with good or acceptable oral health in order to maintain oral health. The composition in this case may control dental plaque formation and minimise the destructive effects of certain plaque bacteria on the periodontal health of the animal.

5

Alternatively, the composition may be used for an animal with poor oral health in order to improve the oral health of the animal. The improvement of oral health may be by way of the control of the further accumulation of dental plaque and slow the progression of the disease into the severest stages. It may also reduce dental plaque already present on the surface of the teeth of the animal. In cases of moderate to severe periodontal disease, the animal may require veterinary and/or dental attention prior to using the composition in order to achieve oral health benefits and reduce the frequency of future veterinary and/or dental intervention.

10

The composition is an oral composition. By oral composition it is meant that during use the oral cavity of the animal is exposed to the composition, and preferably the composition has direct contact with the surface of a tooth of the animal. Most preferably, the surface of a tooth is directly contacted with the *Alchemilla vulgaris* of the composition.

20

Such an oral composition can include toothpaste, mouthwash or any other such gel, liquid or paste. The oral composition may be a foodstuff, as previously defined.

A third aspect of the invention provides the use of *Alchemilla vulgaris* in the manufacture of a composition for the improvement or maintenance of oral health in an animal. Preferably, the oral health is improved or maintained by the control or reduction of dental plaque in the animal including reduction and/or inhibition of disease causing factors, biomass or pathogenic bacteria. The use of *Alchemilla vulgaris* in the manufacture of a composition for the prevention or treatment of gingivitis is also provided.

25

30

## 11

The invention, as a fourth aspect, also provides a method for the improvement or maintenance of oral health in an animal comprising administering to the animal *Alchemilla vulgaris* or a composition of the second aspect. Preferably, the method improves or maintains the oral health of the animal by the reduction or control of dental plaque in the animal, as previously defined.

In the method of the fourth aspect, the oral cavity of the animal is exposed to the composition, by way of consumption of the composition through its inclusion in a foodstuff, or by way of a coating comprising the composition on a toy which the animal chews.

Preferably, the method is for use in an animal susceptible to poor oral health or dental plaque, gingivitis or periodontal disease.

The composition may be administered to an animal with poor oral health to reduce the amount of dental plaque or factors contained therein, and then continued feedings may be carried out to control, reduce or inhibit the formation of further dental plaque or any one or more of the factors contained therein. The animal may require veterinary and/or dental treatment before or during use of the composition to remove calculus deposits in order to see a beneficial effect of the *Alchemilla vulgaris* or the composition.

By poor oral health is meant the presence of a number of indicators of this status including calculus and plaque accumulation, gingivitis, oral malodour, presence of gingival recession and/or periodontal pockets, as will be appreciated by the skilled person.

All features of each aspect of the invention relate to all other aspects *mutatis mutandis*, as appreciated by the skilled person.

The invention will now be described with reference to the following non-limiting examples and figure, in which:

Figure 1 shows the effect of *Alchemilla vulgaris* on *Peptostreptococcus stomatis* colonies cultured from treated single species biofilms expressed as a percentage of untreated controls. Untreated CFU (100%) =  $1.34 \times 10^7$ .

5

### EXAMPLES

*Alchemilla vulgaris* was tested for its ability to control or reduce dental plaque in an animal by way of the following *in vitro* experiments. Supragingival plaque was obtained from cats and various assays were carried out, as described below, to determine whether *Alchemilla vulgaris* has the ability to improve or maintain oral health in an animal.

10

#### Example 1

Initial assays were set up to help determine whether *Alchemilla vulgaris* would be suitable for use in an animal for improving or maintaining oral health.

15

These assays included ability to inhibit adhesion of plaque forming bacterial strains and ability to inhibit protease production in such bacterial strains.

*Alchemilla vulgaris* inhibited adhesion of biofilm forming bacterial strains by up to 100% and protease production by up to 66%. *Alchemilla vulgaris* also showed inhibition of haemolysis in 2 out of 8 bacterial strains tested.

20

These results indicated that *Alchemilla vulgaris* is able to inhibit undesirable oral bacteria and therefore it was tested in further assays for its ability to improve or maintain oral health.

25

#### Example 2

##### Assay inoculum: plaque and saliva sampling from dogs

The assay requires fresh supragingival feline dental plaque and saliva for inoculation. The inoculum consists of pooled dental plaque and unfiltered saliva sampled from a group of 18 cats, varying in age, breed and oral health status.

30

The plaque and saliva were resuspended in artificial saliva to form the inoculum of approximately 10% plaque and 30% saliva.

## 5     Assay set-up

10     The plate biofilm assay (PBA) utilises a 24 well plate format in which biofilms, representative of feline dental plaque, are grown on hydroxyapatite (HA) discs. Prior to being introduced to the 24 well assay plate, each HA disc is preconditioned for 2 hours in a solution of 50% filter sterilised feline saliva in artificial feline saliva. The preconditioning step stimulates the formation of a salivary pellicle on the HA disc surface. Following preconditioning, each HA disc is placed individually into a well on the 24 well plate. The inoculum is divided into two equal aliquots and the active added to one aliquot at the appropriate concentration. The other aliquot represents the control (no active). A 1ml inoculum is added to each well and the assay plate incubated aerobically with shaking at 38°C for 48 hours. After 24 hours and 30 hours, the discs are transferred into fresh artificial saliva containing the active at the appropriate concentration as before. Biofilm-covered HA discs are removed from the assay plate for analysis after 48 hours. Each HA disc, with the exception of those being used for biomass quantification, is placed into 500µl PBS and vortex mixed for 30 seconds to remove biofilm growth from the disc into solution. Biofilm suspensions are then used for analysis. Biofilm-covered HA discs that are being used for biomass quantification are removed from the 24 well assay plate and used directly in the crystal violet assay.

25

## Example 3

### *Alchemilla vulgaris* extracts tested in the PBA

30     The extract of *Alchemilla vulgaris* used was a methanol extract (M) for testing in the feline PBA since this showed good activity in the initial screening rounds. Extractions were performed as described previously.

In addition, chlorhexidine (Lloyds Pharmacy) was included as the gold standard reference or positive control. However, chlorhexidine is undesirable for use in animal compositions since it is a synthetic chemical and may have potential toxic effects as it is a chemical used in its purest form.

5

#### Example 4

##### Biofilm measures

The following analyses were used to assess the biofilms produced in the feline PBA and the effects of *Alchemilla vulgaris* and the non-botanical compounds on biofilm development:

10

Biomass quantification (crystal violet assay)

Protease activity

Bacterial viable counts

15

A brief description of each biofilm measure is given below.

##### Biomass

The total amount of biofilm grown on the HA discs was quantified using the crystal violet staining method. Biomass was represented as being directly proportional to the OD reading at 595nm (OD<sub>595</sub>) of the samples compared to controls. Results were expressed as the reduction in OD<sub>595</sub> seen in active-treated samples compared to no active controls, reflecting the effect of the active treatment on the amount of biofilm growth on the disc.

20

*Alchemilla vulgaris* reduced biomass by 85.6%.

25

##### Protease activity

Trypsin-like protease activity was measured using the liquid BAPNA assay, a colourimetric assay in which the amount of trypsin present in a sample is directly proportional to the intensity of the colour developed. Samples were quantified against

30

a trypsin standard curve and results expressed as the percentage inhibition of protease activity in active-treated samples compared to controls.

*Alchemilla vulgaris* reduced protease production by 100%.

5

#### Bacterial counts

Viable numbers of bacteria were quantified using Columbia blood agar plates supplemented with haemin and menadione. Aerobes were counted after incubation for 2 days and anaerobes, including black pigmenting colonies (BPC), were counted after incubation at appropriate conditions for 9 days. Plate counts are expressed as colony forming units (cfu) per ml and differences between control and active plates are expressed in logs.

10

15

*Alchemilla vulgaris* reduced plate counts of black pigmenting colonies by 5.9 logs, compared to the controls.

#### Example 5

##### Statistical analysis of data

Each sample was repeated 5 times within the assay. Unless otherwise stated, all extracts were tested in the assay at a concentration of 500  $\mu\text{g/ml}$ . For each sample, all of the values obtained were logged and the means calculated from the log values.

20

25

A 2-tailed t-test with unequal variance was then performed. An unequal variance analysis was selected as the individual analyses were independent i.e. the measures were not comparable to one another. For each data set, p values were obtained and these gave an indication of the reproducibility of the data.

30



## Results

A table summarising how *Alchemilla vulgaris* performed in the tests is set out below. Aerobes, anaerobes and black pigmenting colonies (BPC) are expressed as log reductions and protease and biomass are expressed as percentage reductions.

Name	Aerobe (Log 10 reduction)	Anaerobe (Log 10 reduction)	BPC (Log 10 reduction)	Protease (% reduction)	Biomass (% reduction)
Chlorhexidine	1.91	2.16	4.86	90.0	79.0
<i>Alchemilla vulgaris</i>	1.33	0.87	5.90	100	85.6
<i>Uncaria tomentosa</i>	0.48	0.12	0.23	100	78.1
<i>Camellia sinensis</i>	0	0	0.27	23.0	17.0

Table 1

*Alchemilla vulgaris* had a significant inhibitory effect on black pigmenting colony counts, protease production and biomass.

10

*Camellia sinensis* is well known in the art to have a strong effect on human plaque bacteria. It can be seen from the results above that *Alchemilla vulgaris* is more effective at inhibiting plaque bacteria in feline plaque than *Camellia sinensis*, and thus provides a surprising new botanical ingredient for use in the maintenance or improvement of oral health in an animal.

15

## Example 6

20

### Testing of raw material

The raw plant material of *Alchemilla vulgaris* was also tested in the Plate Biofilm Assay, as well as the extracts described above. The raw plant material was prepared through a 250µm pore size sieve and was tested at 5000µg/ml in the assay. The raw material was also effective at inhibiting the biofilm and reduced biomass by up to 83.8%, and protease by up to 82.4%.

#### Example 7

##### Inhibition of human plaque isolates

*Alchemilla vulgaris* powder was also tested for inhibition of biofilm formation in a human form of the Plate Biofilm Assay using an organism *Peptostreptococcus stomatis* commonly found in human plaque. The final concentration of each agent was 250 µg/ml. Tests were repeated five times in separate assays.

Hydroxyapatite discs were incubated in 20% sterile pooled human saliva for 2 hours at room temperature before inoculation with *Peptostreptococcus stomatis* in artificial saliva (Pratten *et al.*, 1998). Biofilms were cultured for 24 hours at 37°C in anaerobic conditions (10% H<sub>2</sub>, 10% CO<sub>2</sub>, 80% N<sub>2</sub>), mimicking the conditions found in the sub-gingival recesses during the onset and progression of periodontitis.

Biofilms were dispersed, serially diluted and plated onto columbia blood agar containing hemin and menadione (5mg/l) before incubation under anaerobic conditions. Colonies were counted after 24 hours growth at 37°C.

As can be seen in Figure 1, treatment of the biofilms with *Alchemilla vulgaris* reduced bacterial numbers in *Peptostreptococcus* biofilms compared to both untreated controls and those treated with eucalyptus leaf powder a commonly used natural botanical in oral health applications.

#### Example 8

Various product applications will require survival of the raw material activity following exposure to temperatures up to 120°C. To test this, the *Alchemilla vulgaris*

## 18

was heated to 120°C for 10 minutes and its activity tested in the Plate Biofilm Assay compared with non heat-treated controls.

- 5 Heat treatment of *Alchemilla vulgaris*, as described above, does not affect its performance. Heat-treated *Alchemilla vulgaris* reduces biomass by 66.2%, compared to 45.2% in the unheated control. Protease production is inhibited by 100% by both the heat-treated and non-heated material.


Claims

1. *Alchemilla vulgaris* for use in the maintenance or improvement of oral health in an animal.
- 5 2. *Alchemilla vulgaris* according to claim 1, for use in the prevention or treatment of gingivitis in an animal.
- 10 3. *Alchemilla vulgaris* according to claim 1 or claim 2, wherein the *Alchemilla vulgaris* reduces, inhibits or controls disease causing factors produced by plaque and/or dental plaque in the oral cavity of the animal.
- 15 4. *Alchemilla vulgaris* according to any one of claims 1 to 3, wherein the *Alchemilla vulgaris* alters the bacterial content of dental plaque in the oral cavity of the animal.
- 20 5. *Alchemilla vulgaris* according to claim 4, wherein the *Alchemilla vulgaris* alters the bacterial content by reducing the bacterial content.
- 25 6. *Alchemilla vulgaris* according to any one of claims 1 to 5, wherein the *Alchemilla vulgaris* improves the health of dental plaque present in the oral cavity of the animal.
7. *Alchemilla vulgaris* according to any one of claims 1 to 4, wherein the *Alchemilla vulgaris* reduces or inhibits inflammatory proteases and/or pathogenic bacteria in dental plaque.
- 30 8. *Alchemilla vulgaris* according to claim 7, wherein the pathogenic bacteria include black pigmented anaerobes.
9. *Alchemilla vulgaris* according to claim 7, wherein the pathogenic bacteria include *Peptostreptococcus*.
- 35 10. *Alchemilla vulgaris* according to claims 1 to 9, wherein the animal is a cat, a dog or a human.

11. An oral composition comprising *Alchemilla vulgaris* .
12. The composition according to claim 11, for use as set out in any one of claims  
5 1 to 10.
13. The composition according claim 11 or claim 12, wherein the *Alchemilla  
vulgaris* is present at a concentration of from 0.1% to 20% by weight of the  
composition.  
10
14. The composition according to any one of claims 11 to 14, wherein the  
composition is a foodstuff.
15. The use of *Alchemilla vulgaris* in the manufacture of a composition for the  
15 improvement or maintenance of oral health in an animal.
16. The use of *Alchemilla vulgaris* in the manufacture of a composition for the  
prevention or treatment of gingivitis in an animal.
- 20 17. The use according to claim 15 or 16, wherein the composition reduces or  
controls dental plaque in the animal.
18. A method of maintaining or improving oral health in an animal comprising  
administering to the animal an effective amount of *Alchemilla vulgaris* or the  
25 composition according to claim any one of claims 11 to 14.
19. *Alchemilla vulgaris* for use as essentially as described in the examples.
20. An oral composition essentially as described in the examples.  
30
21. A method of maintaining or improving oral health of an animal essentially as  
described in the examples.

1/1

FIGURE 1



## INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2007/004522

A. CLASSIFICATION OF SUBJECT MATTER  
 INV. A61Q11/00 A61K8/97

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, EMBASE, CHEM ABS Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/74668 A (SHRIVASTAVA) 14 December 2000 (2000-12-14) example 6 page 10 claims 9,10	1,10-12, 15,18-20
X	DE 197 12 659 C1 (WEBER & WEBER) 20 August 1998 (1998-08-20) column 1, line 58 - column 2, line 7 claims	1,10-12, 15,18-21
X	WO 93/11676 A (VAN LEUVEN) 24 June 1993 (1993-06-24) page 7, line 5 - line 19 claims; examples	11,12, 14,15,20
	----- -/-- -----	

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the International search

21 February 2008

Date of mailing of the international search report

05/03/2008

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Irwin, Lucy

## INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2007/004522

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99/34811 A (FARMO NAT LTD) 15 July 1999 (1999-07-15)  page 3, line 20 - line 26 page 7, line 8 - line 28 claims -----	1,5,7, 10-12, 15,18-21
X	FR 2 461 499 A (INVERNI DELLA BEFFA) 6 February 1981 (1981-02-06)  claims; examples -----	1,3-5,7, 10-12, 15,17-21
X	WO 01/15680 A (VAN BEEK GLOBAL) 8 March 2001 (2001-03-08) claims -----	1
A	US 1 466 578 A (CLIFTON) 28 August 1923 (1923-08-28) the whole document -----	1-21
E	WO 2008/010188 A (AD MED BIOTECHNOLOGY) 24 January 2008 (2008-01-24) claims -----	1



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB2007/004522

### Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 18, 21  
because they relate to subject matter not required to be searched by this Authority, namely:  
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers allsearchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search reportcovers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2007/004522

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0074668	A	14-12-2000	AT 259638 T	15-03-2004
			AU 781964 B2	23-06-2005
			AU 7224400 A	28-12-2000
			CA 2376367 A1	14-12-2000
			DE 69914957 D1	25-03-2004
			DE 69914957 T2	23-12-2004
			EP 1194136 A1	10-04-2002
			HK 1045813 A1	26-11-2004
			PT 1194136 T	30-07-2004
			US 6964783 B1	15-11-2005
DE 19712659	C1	20-08-1998	AT 203674 T	15-08-2001
			AU 7210298 A	20-10-1998
			WO 9842357 A1	01-10-1998
			EP 0975350 A1	02-02-2000
			ES 2162441 T3	16-12-2001
			JP 2001518921 T	16-10-2001
			US 6395309 B1	28-05-2002
WO 9311676	A	24-06-1993	AU 3268893 A	19-07-1993
			CA 2126074 A1	24-06-1993
			DE 69221635 D1	18-09-1997
			DE 69221635 T2	26-03-1998
			EP 0616496 A1	28-09-1994
			ES 2108257 T3	16-12-1997
			GR 3025349 T3	27-02-1998
			NL 9102102 A	16-07-1993
			US 5513663 A	07-05-1996
WO 9934811	A	15-07-1999	AU 1949999 A	26-07-1999
			CA 2317644 A1	15-07-1999
			EP 1051185 A1	15-11-2000
			US 6197305 B1	06-03-2001
FR 2461499	A	06-02-1981	DE 3027933 A1	26-02-1981
			IT 1209454 B	30-08-1989
WO 0115680	A	08-03-2001	AT 246498 T	15-08-2003
			AU 780608 B2	07-04-2005
			AU 6783100 A	26-03-2001
			CA 2382337 A1	08-03-2001
			DE 60004374 D1	11-09-2003
			EP 1207865 A1	29-05-2002
			MX PA02002308 A	16-07-2004
			NZ 517585 A	29-08-2003
			US 2003032678 A1	13-02-2003
			US 6414036 B1	02-07-2002
US 1466578	A	28-08-1923	NONE	
WO 2008010188	A	24-01-2008	US 2008026083 A1	31-01-2008